TabletsClinical Overview
Deflazacort (30mg) and Tamsulosin (0.4mg) Tablets is a specialized medical expulsive therapy (MET) combination. Tamsulosin blocks alpha-1D receptors located predominantly in the lower third of the ureter and ureterovesical junction (UVJ), inhibiting ureteral smooth muscle spasm and dilating the ureteral lumen. Deflazacort is an oxazoline glucocorticoid that exerts potent anti-inflammatory and anti-edematous action around the impacted stone site, reducing localized mucosal swelling and pain. Indicated for medical expulsive therapy of distal ureteral calculi (stones measuring 5 to 10 mm) to accelerate spontaneous stone passage and reduce surgical intervention.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with food for a short course of 7 to 14 days, as directed by the urologist. Drink plenty of water (at least 2.5 to 3 liters daily) to promote diuresis and stone expulsion.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, headache, retrograde ejaculation, transient epigastric discomfort, insomnia, fluid retention. Rare/Severe: Orthostatic hypotension, hyperglycemia, peptic ulceration, and stone impaction requiring emergency stenting.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Short-term treatment only (7-14 days). Discontinue immediately and seek emergency urological evaluation if fever, chills, intractable colic pain, or anuria develops (indicative of obstructive urosepsis). Caution in diabetes and active peptic ulcer disease.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.
Deflazacort Tablets 6 mg
Deflazacort Tablets (6mg) is an oral synthetic oxazoline derivative of prednisolone on the PMBI formulary. It exerts powerful anti-inflammatory and immunosuppressive actions with significantly lower bone mineral resorption, reduced osteoclastogenesis, and lower diabetogenic/weight gain liability compared to conventional prednisone or dexamethasone. Indicated for severe refractory bronchial asthma, allergic disorders, and Duchenne muscular dystrophy.
Tamsulosin Hydrochloride (Modified Release) 0.4mg + Dutasteride 0.5mg Tablets
Tamsulosin Hydrochloride (0.4mg modified-release) and Dutasteride (0.5mg) Tablets/Capsules is a synergistic dual-action therapy on the WHO Model List framework for symptomatic Benign Prostatic Hyperplasia (BPH). Tamsulosin is a uroselective alpha-1A/1D adrenergic receptor antagonist that relaxes smooth muscle in the prostate stroma, prostatic capsule, and bladder neck, rapidly improving urinary peak flow rates and relieving lower urinary tract symptoms (LUTS). Dutasteride is a potent dual type 1 and type 2 5-alpha reductase inhibitor (5-ARI) that suppresses dihydrotestosterone (DHT) synthesis by >90%, progressively shrinking enlarged prostate volume over 3-6 months. Indicated for moderate-to-severe BPH with enlarged prostate (volume >30cc) to reduce the risk of acute urinary retention (AUR) and the need for BPH-related surgery (TURP).
Tamsulosin Hydrochloride Prolonged Release Capsules 0.4mg
Tamsulosin Hydrochloride Prolonged Release Capsules (0.4mg) is a uroselective alpha-1A and alpha-1D adrenergic receptor antagonist on the WHO Model List of Essential Medicines. By selectively blocking alpha-1A receptors concentrated in the human prostate, bladder neck, and prostatic urethra (which account for 70% of prostatic alpha receptors), it relaxes smooth muscle tone, reduces outflow resistance, and enhances maximum urinary flow rate (Qmax) with minimal effect on systemic vascular resistance. Indicated for symptomatic Benign Prostatic Hyperplasia (BPH) and as off-label medical expulsive therapy for distal ureteric stones.
Tamsulosin Hydrochloride 0.4mg + Tolterodine Tartrate 2mg Extended Release Capsules
Tamsulosin Hydrochloride (0.4mg) and Tolterodine Tartrate (2mg/4mg Extended Release) Capsules is a fixed-dose combination for men suffering from mixed storage and voiding lower urinary tract symptoms (LUTS). Tamsulosin relieves voiding symptoms (hesitancy, weak stream, straining) via alpha-1A adrenergic blockade, while tolterodine competitively antagonizes muscarinic M2/M3 receptors in the detrusor muscle, abolishing involuntary bladder spasms and relieving storage symptoms (frequency, urgency, nocturia). Indicated for men with BPH and co-existing Overactive Bladder (OAB).